Day: September 26, 2023

VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announced today that it has engaged SagePoint Capital Partners Inc. (“SagePoint”) to provide strategic capital markets and corporate development advisory services for the Company. SagePoint will provide EnWave with a comprehensive capital markets plan to expand its profile with high-net worth and institutional investors. EnWave is to remunerate SagePoint at the rate of CAD$13,333 per month and the service agreement is subject to termination upon thirty days-notice by either party after the first three months of service. Additionally, the Company has granted SagePoint an aggregate of 250,000 incentive stock options (the “Options”). The grant of Options is subject to the terms of the Company’s...

VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) — American Future Fuel Corporation (CSE: AMPS; OTCQB: AFFCF; FWB: K14, WKN: A3DQFB) (the “Company” or “American Future Fuel”), is pleased to announce the appointment of Mr. Michael Henrichsen as a new member of the Board of Directors, effective September 25, 2023. Mr. Henrichsen’s extensive expertise as a structural geologist and his remarkable track record in enhancing reserves and resources make him a valuable addition to the Company’s leadership team. Mr. Henrichsen brings a wealth of experience from his tenure in the mining industry, where he played a pivotal role in shaping the landscape at companies such as Newmont Corporation (with a market capitalization of approximately $43 billion (CAD)) and others: Newmont Corp 2008 – 2011: Mr. Henrichsen led the technical...

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its underwritten public offering of an aggregate of 15,700,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being sold at a public offering price of $0.51 per share (inclusive of the Pre-Funded Warrant exercise price of $0.01). All of the shares and Pre-Funded Warrants in the offering are being sold by the Company. Total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $8 million. In addition, the Company...

Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows:Date Tuesday, September 26, 2023Time 12:25 PM ETLocation New YorkWebcast Link https://wsw.com/webcast/cantor19/nvct/2113419About Nuvectis Pharma, Inc.Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of...